Tyrosine kinase inhibitors in oncology - Part 2: Clinical applications and perspectives;Tyrosinkinaseinhibitoren in der tumortherapie - Teil 2: Aktueller stand und perspektiven

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 23, 2005, Pages 1438-1442

  Grimm, Christian F ^a   Blum, H E ^a   Geissler, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BCR ABL PROTEIN; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CETUXIMAB; CGP 59326; CISPLATIN; CYTARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; IDARUBICIN; IMATINIB; INTERFERON; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PERTUZUMAB; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB;

ALLERGIC REACTION; ANGIOGENESIS; BREAST CARCINOMA; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LUNG CARCINOMA; ONCOLOGY; PATIENT SELECTION; REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; GENES, ABL; HUMANS; NEOPLASMS; PATIENT SELECTION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 20844462257     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870836     Document Type: Review

References (17)

1. Agus DB et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2: 127-137
2. Apperley JF et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481-487
3. Arteaga CL, Selecting the right patient for tumor therapy. Nat Med 2004; 10: 577-578
4. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-1295
5. Ciardiello F et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063
6. Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345
7. Demetri GD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480
8. Griffin RJ et al. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 2002; 62: 1702-1706
9. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94: 1593-1611
10. Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
11. Kantarjian HM et al. Long-Term Survival Benefit and Improved Complete Cytogenetic and Molecular Response Rates with Imatinib Mesylate in Philadelphia Chromosome-Positive, Chronic-Phase Chronic Myeloid Leukemia after Failure of Interferon-{alpha}. Blood 2004; 15: 15
12. Ross DM, Hughes TP. Cancer treatment with kinase inhibitors: what have we learnt from imatinib? Br J Cancer 2004; 90: 12-19
13. Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792
14. Terre C et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004; 18: 1340-1346
15. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487-491
16. Wood JM et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189
17. Xiong HQ et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004; 22: 2610-2616